JP2025508963A5 - - Google Patents

Info

Publication number
JP2025508963A5
JP2025508963A5 JP2024552169A JP2024552169A JP2025508963A5 JP 2025508963 A5 JP2025508963 A5 JP 2025508963A5 JP 2024552169 A JP2024552169 A JP 2024552169A JP 2024552169 A JP2024552169 A JP 2024552169A JP 2025508963 A5 JP2025508963 A5 JP 2025508963A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063559 external-priority patent/WO2023168326A2/en
Publication of JP2025508963A publication Critical patent/JP2025508963A/ja
Publication of JP2025508963A5 publication Critical patent/JP2025508963A5/ja
Pending legal-status Critical Current

Links

JP2024552169A 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法 Pending JP2025508963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316140P 2022-03-03 2022-03-03
US63/316,140 2022-03-03
PCT/US2023/063559 WO2023168326A2 (en) 2022-03-03 2023-03-02 Humanized and affinity-matured anti-ceacam1 antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2025508963A JP2025508963A (ja) 2025-04-10
JP2025508963A5 true JP2025508963A5 (cg-RX-API-DMAC7.html) 2026-03-09

Family

ID=87884376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552169A Pending JP2025508963A (ja) 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法

Country Status (7)

Country Link
US (1) US20250388666A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486380A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025508963A (cg-RX-API-DMAC7.html)
CN (1) CN119032103A (cg-RX-API-DMAC7.html)
AU (1) AU2023227877A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245215A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023168326A2 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US9556271B2 (en) * 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells

Similar Documents

Publication Publication Date Title
JP2022515318A5 (cg-RX-API-DMAC7.html)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020103301A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2021500853A5 (cg-RX-API-DMAC7.html)
JP2018532383A5 (cg-RX-API-DMAC7.html)
JP2020508334A5 (cg-RX-API-DMAC7.html)
JP2018510636A5 (cg-RX-API-DMAC7.html)
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
JP2021517152A5 (cg-RX-API-DMAC7.html)
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2022521705A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2021533796A5 (cg-RX-API-DMAC7.html)
JP2023511898A5 (cg-RX-API-DMAC7.html)
JP2024515560A5 (cg-RX-API-DMAC7.html)
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
JP2021529776A5 (cg-RX-API-DMAC7.html)
JP2021523949A5 (cg-RX-API-DMAC7.html)
CN111655287A (zh) Ildr2拮抗剂及其组合
JP2022513729A5 (cg-RX-API-DMAC7.html)
Safdari et al. humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII